Atara Biotherapeutics, Inc.ATRAEarnings & Financial Report
Nasdaq
NextMar 31, 2026
ATRA Q3 2025 Key Financial Metrics
Revenue
$3.5M
Gross Profit
N/A
Operating Profit
$-3.6M
Net Profit
$-4.3M
Gross Margin
N/A
Operating Margin
-103.5%
Net Margin
-124.6%
YoY Growth
-91.4%
EPS
$-0.32
Financial Flow
Atara Biotherapeutics, Inc. Q3 2025 Financial Summary
Atara Biotherapeutics, Inc. reported revenue of $3.5M for Q3 2025, with a net profit of $-4.3M (-124.6% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $3.5M |
|---|---|
| Net Profit | $-4.3M |
| Gross Margin | N/A |
| Operating Margin | -103.5% |
| Report Period | Q3 2025 |
Atara Biotherapeutics, Inc. Annual Revenue by Year
Atara Biotherapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $128.9M).
| Year | Annual Revenue |
|---|---|
| 2024 | $128.9M |
| 2023 | $8.6M |
| 2022 | $63.6M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.3M | $27.4M | $28.6M | $40.2M | $32.8M | $98.1M | $17.6M | $3.5M |
| YoY Growth | 1824.0% | 2131.4% | 2892.7% | 1779.8% | 670.3% | 258.8% | -38.6% | -91.4% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $165.5M | $165.3M | $117.3M | $142.7M | $109.1M | $62.0M | $36.9M | $30.2M |
| Liabilities | $264.7M | $263.6M | $228.2M | $233.2M | $206.4M | $117.1M | $71.9M | $66.8M |
| Equity | $-99.2M | $-98.3M | $-110.9M | $-90.5M | $-97.3M | $-55.1M | $-35.0M | $-36.6M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-50.4M | $-29.6M | $-10.6M | $-4.0M | $-24.5M | $-28.1M | $-7.3M | $-9.8M |